BioSpace News Archive

Ceruvia Lifesciences, a leading neurotransformational biopharmaceutical company, today announced the first participant has been dosed in their Phase 1 clinical trial of NYPRG-101 (2-bromo- d -lysergic acid diethylamide) in healthy adult participants.

Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) today announced the appointments of Roelof Rongen, MSE, MBA as Chief Executive Officer and Director, and Mark C. Rogers, MD, MBA as a member of the Company’s Board of Directors.

Biobeat today announced the publication of clinical data demonstrating that the company’s remote patient monitoring wrist device may be utilized for noninvasive wearable multi-parameter monitoring during diuresis in heart failure (HF) patients.

The Diagnostic Ultra-portable X-ray for Space (DUXS) program achieved liftoff late last year by successfully obtaining medical diagnostic radiographic images in zero-gravity (Zero-G) conditions – including a re-creation of one of the first X-ray images ever taken by Nobel Prize winner Wilhelm Conrad Röntgen.

Shanghai LePure Biotech Co., Ltd. (“LePure” or “LePure Biotech”) announced the completion of its Series C financing from a consortium of world-renowned investors co-led by Novo Holdings,General Atlantic and Goldman Sachs Asset Management, with participation from existing investors including Highlight Capital, Bayland Capital, HM Capital.

SFJ Pharmaceuticals (“SFJ” or the “company”) today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) to SFJ.

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent (Patent No. US 11,555,070) for its anti-claudin 18.2 antibodies.

Land Science®, a division of REGENESIS®, and the recognized leader in contaminant vapor intrusion mitigation technologies, was recently awarded a U.S. patent for the innovative use of a reinforced geomembrane comprised of an encapsulated, metalized layer and installed with Nitra-Core™, a spray-applied nitrile-modified asphalt.

AposHealth, a medical device company providing first-in-class solutions to treat musculoskeletal conditions, today announced the appointment of Harry L. Leider, MD, MBA as its new Chief Medical Officer (CMO) and Executive Vice President.

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson’s disease, today announced the top-line results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs).